Quantitative risk-benefit analysis of a calcium channel antagonist during regulatory review.

被引：0
|
作者：
Nguyen, B [1 ]
Marroum, PJ [1 ]
Gobburu, JV [1 ]
机构：
[1] US FDA, Rockville, MD 20857 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2003年 / 73卷 / 02期
关键词：
D O I：
10.1016/S0009-9236(03)90476-0
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P33 / P33
页数：1
相关论文
共 50 条
  • [1] Quantitative risk-benefit analysis of natalizumab
    Thompson, J. P.
    Noyes, K.
    Dorsey, E. R.
    Schwid, S. R.
    Holloway, R. G.
    NEUROLOGY, 2008, 71 (05) : 357 - 364
  • [2] QUANTITATIVE RISK-BENEFIT ANALYSIS OF NATALIZUMAB
    Steiner, Israel
    NEUROLOGY, 2009, 72 (20) : 1791 - 1791
  • [3] Calcium antagonists in the elderly - A risk-benefit analysis
    Schwartz, JB
    DRUGS & AGING, 1996, 9 (01) : 24 - 36
  • [4] RISK-BENEFIT ANALYSIS IN REGULATORY DECISION-MAKING
    HIGHLAND, JH
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1979, 329 (OCT) : 263 - 266
  • [5] Risk-Benefit Analysis of Seafood Consumption: A Review
    Hellberg, Rosalee S.
    DeWitt, Christina A. Mireles
    Morrissey, Michael T.
    COMPREHENSIVE REVIEWS IN FOOD SCIENCE AND FOOD SAFETY, 2012, 11 (05): : 490 - 517
  • [6] QUANTITATIVE RISK-BENEFIT ANALYSIS IN REGULATORY DECISION-MAKING - A FUNDAMENTAL PROBLEM AND AN ALTERNATIVE PROPOSAL
    BOGEN, KT
    JOURNAL OF HEALTH POLITICS POLICY AND LAW, 1983, 8 (01) : 120 - 143
  • [7] Risk-benefit analysis
    Mossman, KL
    HEALTH PHYSICS, 2002, 82 (05): : 750 - 750
  • [8] Risk-benefit analysis
    Wilson, R.
    Crouch, E.A.C.
    Physics Today, 2002, 55 (10)
  • [9] RISK-BENEFIT ANALYSIS
    ZENCEY, M
    ATLANTIC, 1979, 243 (04): : 37 - 37
  • [10] Fish consumption during child bearing age: A quantitative risk-benefit analysis on neurodevelopment
    Zeilmaker, Marco J.
    Hoekstra, Jeljer
    van Eijkeren, Jan C. H.
    de Jong, Nynke
    Hart, Andy
    Kennedy, Marc
    Owen, Helen
    Gunnlaugsdottir, Helga
    FOOD AND CHEMICAL TOXICOLOGY, 2013, 54 : 30 - 34
12345